Hoth Therapeutics Received Institutional Review Board Approval From The Montefiore Medical Center And The Dana-Farber Cancer Institute To Proceed With Its First-In-Human Phase 2a Clinical Trial Of HT-001 For The Treatment Of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has received approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with a Phase 2a clinical trial of HT-001, targeting skin toxicities from Epidermal Growth Factor Receptor Inhibitors.
September 05, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hoth Therapeutics has received approval to start a Phase 2a clinical trial for HT-001, which could potentially address skin toxicities from EGFR inhibitors. This development marks a significant step in their clinical research efforts.
The approval to proceed with the Phase 2a trial is a positive development for Hoth Therapeutics, as it indicates progress in their clinical pipeline. Successful trials could lead to new treatments and potential revenue streams, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100